Saturday 17 October 2026
Export BDX’s income statement to Excel — free account
Becton, Dickinson and Company
BDX Healthcare Medical Instruments & Supplies
In the quarter to June 2026, revenue grew 5.44%, EPS fell 31.5%, free cash flow fell 31.6% and total debt fell 22.9%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for three.
191.75
2.01
−1.04%
Follow BDX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
45.58 | 39.81 | 24.89 | 25.20 |
+8 more quarters Free account |
P/S ratio |
1.86 | 1.99 | 1.99 | 1.94 | |
P/FCF ratio |
12.98 | 12.63 | 16.56 | 15.85 | |
P/Operating CF |
53.59 | 65.76 | 66.32 | 22.86 | |
P/B ratio |
1.70 | 1.83 | 1.72 | 1.67 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.42 | 2.61 | 2.71 | 2.71 | |
EV/EBITDA |
11.39 | 11.92 | 11.56 | 11.74 | |
EV/Operating CF |
13.71 | 13.54 | 17.52 | 17.25 | |
EV/FCF |
16.93 | 16.54 | 22.60 | 22.16 | |
Quick Ratio |
0.34 | 0.38 | 0.40 | 0.38 | |
Current Ratio |
0.87 | 0.94 | 1.05 | 1.11 | |
Net Debt/EBITDA |
10.32 | 22.33 | 13.63 | 9.58 | |
Debt/Assets |
26.63% | 28.93% | 30.85% | 31.85% | |
Debt/Equity |
0.55 | 0.61 | 0.67 | 0.69 | |
Asset Turnover |
0.42 | 0.42 | 0.40 | 0.39 | |
Operating CF/Net income |
2.06 | (2.16) | 1.72 | 3.76 | |
Capex/Depreciation |
(0.25) | (0.24) | (0.18) | (0.50) | |
Interest Coverage |
5.02 | 0.62 | 3.60 | 6.42 | |
Research and Development Expense of Revenue |
5.18% | 5.28% | 5.83% | 6.16% | |
Selling, General and Administrative Expense of Revenue |
25.31% | 25.73% | 26.52% | 22.50% | |
Intangible Assets out of Total Assets |
0.67 | 0.67 | 0.65 | 0.64 | |
Share Based Compensation of Revenue |
1.10% | 1.23% | 1.73% | 1.06% | |
Graham Net Nets |
(0.44) | (0.42) | (0.47) | (0.49) | |
Graham Number |
81.47 | 87.42 | 110.50 | 107.70 | |
Earnings Yield |
2.19% | 2.51% | 4.02% | 3.97% | |
Free Cash Flow Yield |
7.70% | 7.92% | 6.04% | 6.31% | |
Revenue per Share |
18.13 | 16.80 | 18.39 | 25.96 | |
Operating CF per Share |
2.82 | 2.39 | 2.30 | 6.44 | |
Capex per Share |
(0.52) | (0.45) | (0.38) | (1.31) | |
Free Cash Flow per Share |
2.30 | 1.95 | 1.92 | 5.13 | |
Cash per Share |
3.14 | 3.63 | 3.62 | 2.73 | |
Shareholders Equity per Share |
88.85 | 85.99 | 88.53 | 88.27 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
88.85 | 85.99 | 88.53 | 88.27 | |
Free Cash Flow |
633.00 | 546.00 | 549.00 | 1,475.00 | |
Working Capital |
(1,265.00) | (495.00) | 428.00 | 942.00 | |
Capital Expenditures |
(143.00) | (125.00) | (108.00) | (377.00) | |
Net Current Asset Value |
(18,176.00) | (18,687.00) | (20,370.00) | (20,680.00) | |
EV/EBIT |
23.50 | 24.25 | 22.23 | 22.95 | |
Capex to Sales |
0.03 | 0.03 | 0.02 | 0.05 | |
Price to Operating Income |
18.02 | 18.51 | 16.29 | 16.42 | |
| Other line items | |||||
Average Receivables |
2,653.50 | 2,617.00 | 2,573.00 | 2,714.50 | |
Average Payables |
6,228.50 | 6,010.50 | 6,242.50 | 4,001.00 | |
Average Inventory |
3,632.50 | 3,540.00 | 3,972.50 | 3,496.00 | |
Average Assets |
52,816.50 | 52,649.50 | 54,753.00 | 56,305.50 | |
Average Common Equity |
24,944.50 | 24,686.50 | 25,243.00 | 25,639.50 |
Columns are period end dates